<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="23528">Cytochalasin</z:chebi> D targets actin and is ubiquitous in eukaryotic cells </plain></SENT>
<SENT sid="1" pm="."><plain>When <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D is used as a cytotoxic agent in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy, it causes significant side effects </plain></SENT>
<SENT sid="2" pm="."><plain>To prevent this, <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D can be encapsulated in <z:chebi fb="73" ids="53226,53227">polyethylene</z:chebi> liposomes </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, high-performance liquid chromatography observation of the biodistribution of pegylated liposomal <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-bearing mice showed that liposomal <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D could be conveniently dissolved in water for i.v. injection and that it specifically accumulated in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> tissues, more than natural <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D did </plain></SENT>
<SENT sid="4" pm="."><plain>The half-time of liposomal <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D in the plasma was also significantly longer than that of natural <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D (4h versus 10 min) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="53233">MTT</z:chebi> <z:chebi fb="0" ids="53233">3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</z:chebi> assay showed that liposomal <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D treatment could cause significant inhibition of cell proliferation in vitro in a manner similar to that of natural <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D </plain></SENT>
<SENT sid="6" pm="."><plain>The antitumour activities of liposomal <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D were investigated in B16 <z:hpo ids='HP_0002861'>melanoma</z:hpo>, CT26 colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> and H22 <z:e sem="disease" ids="C0019204" disease_type="Neoplastic Process" abbrv="">hepatoma</z:e> models, and the results indicated that liposomal <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D could significantly inhibit <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> and prolong survival in a manner similar to that of <z:chebi fb="2" ids="27899">cisplatin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>TUNEL-based <z:mpath ids='MPATH_3'>apoptosis</z:mpath> assays showed that liposomal <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D induced significant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>Significant inhibition of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> was observed in mice treated with liposomal <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, no significant side effects were observed in mice treated with liposomal <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D </plain></SENT>
<SENT sid="10" pm="."><plain>Our results show that liposomal <z:chebi fb="0" ids="23528">cytochalasin</z:chebi> D increases solubility and bioavailability, a lower incidence of side effects and improves antitumour effects, indicating its potential as a chemical agent for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
</text></document>